Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2025 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully enrolled; Topline data on track for Q3 2025 Currently available...
September 03, 2025 09:00 ET | Source: GRI Bio, Inc.

GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET LA JOLLA, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
August 14, 2025 09:15 ET | Source: GRI Bio, Inc.

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Live video webcast on Wednesday, August 20th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
July 31, 2025 13:50 ET | Source: GRI Bio, Inc.

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
July 31, 2025 09:00 ET | Source: GRI Bio, Inc.

GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response The Independent Data Monitoring Committee (IDMC) has...
July 22, 2025 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

– Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
July 01, 2025 08:45 ET | Source: GRI Bio, Inc.

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim...
June 26, 2025 08:00 ET | Source: GRI Bio, Inc.

GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date...
May 22, 2025 08:00 ET | Source: GRI Bio, Inc.

GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and...
May 21, 2025 09:15 ET | Source: GRI Bio, Inc.

GRI Bio to Participate in the Virtual Investor Closing Bell Series

Live webcast on Wednesday, May 28th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an...